Sector ratings Charles River Laboratories International, Inc.

Stocks

Real-time Estimate Cboe BZX 11:28:47 2026-08-13 am EDT			5-day change	1st Jan Change
285.28 ^USD	+0.32%		+7.80%	+43.48%

Aug. 10	TD Cowen Adjusts PT on Charles River Laboratories International to $300 From $235, Maintains Buy Rating	MT
Aug. 10	Rothschild & Co Redburn Adjusts PT on Charles River Laboratories International to $318 From $241, Maintains Buy Rating	MT

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	13.58B		AA
LONZA GROUP AG	48.72B		AAA
REVOLUTION MEDICINES, INC.	43.99B	-	B	-	-
BEONE MEDICINES AG	40.82B		-
IQVIA HOLDINGS INC.	39.79B		AAA
CELLTRION, INC.	32.7B		A
MEDPACE HOLDINGS, INC.	16.66B		BBB
ASCENDIS PHARMA A/S	16.84B	-	-	-	-
EUROFINS SCIENTIFIC SE	13.95B		AA
ICON PUBLIC LIMITED COMPANY	12.9B		AAA
PHARMARON BEIJING CO., LTD.	11.82B		AA
BIO-TECHNE CORPORATION	11.26B		AA
ABIVAX	10.87B	-	BBB	-	-
PRAXIS PRECISION MEDICINES, INC.	10.79B	-	B	-	-
APOGEE THERAPEUTICS, INC.	10.15B	-	B	-	-
TEMPUS AI, INC.	9.85B		A		-
PROTAGONIST THERAPEUTICS, INC.	9.84B		BB		-
IONIS PHARMACEUTICALS, INC.	9.39B	-	A	-	-
KYMERA THERAPEUTICS, INC.	9.48B	-	BBB	-	-
QIAGEN N.V.	8.89B		AAA
Average	19.11B		A
Weighted average by Cap.			A